Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $52.33

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $52.3333.

KNSA has been the subject of a number of research analyst reports. Wells Fargo & Company upped their target price on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Finally, Wedbush boosted their price target on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th.

Kiniksa Pharmaceuticals International Stock Up 4.1%

Shares of KNSA opened at $41.03 on Friday. The firm has a market capitalization of $3.11 billion, a PE ratio of 91.18 and a beta of 0.04. The firm has a 50-day moving average price of $41.35 and a 200 day moving average price of $36.99. Kiniksa Pharmaceuticals International has a 52-week low of $18.12 and a 52-week high of $44.42.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company’s revenue was up 61.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.18) earnings per share. On average, equities analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 82,542 shares of the stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the completion of the sale, the insider directly owned 61,324 shares of the company’s stock, valued at $2,277,573.36. This represents a 57.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the completion of the transaction, the chief operating officer owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 202,230 shares of company stock valued at $8,023,679 over the last quarter. Company insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently modified their holdings of the stock. Aberdeen Group plc lifted its holdings in shares of Kiniksa Pharmaceuticals International by 152.4% during the fourth quarter. Aberdeen Group plc now owns 400,598 shares of the company’s stock valued at $16,525,000 after purchasing an additional 241,876 shares during the last quarter. SG Americas Securities LLC increased its stake in Kiniksa Pharmaceuticals International by 288.6% in the 4th quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after purchasing an additional 402,078 shares in the last quarter. Sound View Wealth Advisors Group LLC raised its holdings in Kiniksa Pharmaceuticals International by 16.2% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 14,792 shares of the company’s stock worth $610,000 after buying an additional 2,063 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Kiniksa Pharmaceuticals International by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after buying an additional 771 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Kiniksa Pharmaceuticals International by 42.3% during the third quarter. JPMorgan Chase & Co. now owns 192,456 shares of the company’s stock valued at $7,473,000 after buying an additional 57,174 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.